Related Experiment Video
Updated: Jan 31, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report
Huan Sun1,2,3, Qini Zhao1,2,3, Yanjing Wang4
1Cardiology Department, China-Japan Union Hospital of Jilin University.
Insights
Switching novel oral anticoagulants (NOACs) may be effective when initial treatment fails. This case study highlights individualized patient response to NOACs for atrial fibrillation stroke prevention.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) management requires effective anti-thrombosis therapy for stroke prevention.
- Novel oral anticoagulants (NOACs) are guideline-recommended for AF, but switching between them is not fully understood.
Observation:
- A 52-year-old male patient with heart failure and AF presented with a left atrial thrombus.
- Cardiomyopathy was diagnosed via cardiac magnetic resonance (CMR) and echocardiography.
Findings:
- Initial treatment with rivaroxaban (20 mg daily) failed to reduce the atrial thrombus.
- Switching to dabigatran (150 mg twice daily) successfully eliminated the thrombus.
Implications:
- Individualized patient responsiveness to NOACs is crucial in clinical practice.
- This case suggests that switching NOACs can be a viable strategy for non-responsive cases.
Rationale:
Anti-thrombosis therapy for atrial fibrillation (AF) management and stroke prevention is an important aspect of disease management. Novel oral anticoagulants (NOACs) are recommended by guidelines for AF management. However, if one can switch one NOAC to another when the former showed a poor effect has not been fully determined.
Patient Concerns:
A 52-year-old man was admitted to our center for heart failure and AF with a thrombus in the left atrium.
Diagnoses:
Cardiomyopathy was diagnosed by cardiac magnetic resonance (CMR) and echocardiography.
Interventions:
He was prescribed rivaroxaban (20 mg daily) as treatment, and dabigatran (150 mg twice daily) was used when the thrombus was found to be non-response to rivaroxaban.
Outcomes:
The rivaroxaban did not diminish the atrial thrombus, and dabigatran was given instead which finally eliminated the thrombus.
Lessons:
Individualized responsiveness to NOACs should be considered and paid more attention to during clinical practice.
Related Concept Videos
Venous Thrombosis I: Introduction
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
Null and Alternative Hypotheses
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...
Data Reporting and Recording
Resistivity

